A clinical trial was stopped early after researchers found that the bone marrow cancer drug pomalidomide is safe and effective for treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder. Patients taking the drug experienced fewer nosebleeds, required fewer blood transfusions, and reported a better quality of life. This is significant, as there were no reliable treatments.
Bone marrow cancer drug may help treat rare bleeding condition
Hope for long-term relief in HHT.
- Advertisement -
Explore more ..
High-fat diets and memory loss- A reversible story
Machine learning identifies early depression signals in facial patterns.
Why alcohol halts liver regeneration, even after quitting
New research links inflammation to faulty RNA processing
Breakthrough stool test could replace invasive colonoscopies
An artificial intelligence-based approach to diagnose colorectal cancer from the gut microbiota.
TRENDING
- Advertisement -